A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% iā¦ (NCT02173223) | Clinical Trial Compass
UnknownPhase 2
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt
United States10 participantsStarted 2014-06
Plain-language summary
A. To evaluate the ocular hypotensive efficacy of the rho-kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in glaucoma patients with failed prior glaucoma filtering surgery and uncontrolled IOP who are facing further surgical intervention. Patients will be treated for 6 months in this initial trial.
B. To evaluate the efficacy of AR-12286 in enabling treated patients to delay or avoid the necessity of further surgical intervention.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Patients older than 18 years of either sex.
ā. Patients with open-angle glaucoma with prior glaucoma filtering surgery.
ā. IOP above the target range or visual field progression.
ā. Have given written informed consent, prior to any investigational procedures.
ā. Ability to attend for the 6-month duration of treatment.
Exclusion criteria
ā. Closed angle glaucoma (primary or secondary).
ā. Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
ā. Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or lubricating drops for dry eye (which may be used throughout the study).
ā. Any abnormality preventing reliable applanation tonometry of the treated eye.
ā. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
ā. Participation in any investigational study within the past 30 days.
ā. Inability to perform reliable visual field testing.